Live price temporarily unavailable.
Lyell Immunopharma (LYEL) is a Health Care company in the Russell 2000. Latest news and coverage below.
| FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | $657.0K | $7.76M | $10.7M | $84.7M | $130.0K | $61.0K | $36.0K |
| Growth (year over year) | — | +1080.5% | +37.3% | +695.1% | −99.8% | −53.1% | −41.0% |
| Operating income | −$102.1M | −$211.9M | −$214.8M | −$187.1M | −$247.0M | −$358.8M | −$269.4M |
| Operating margin | −15538.7% | −2732.6% | −2016.7% | −220.9% | −190006.2% | −588123.0% | −748344.4% |
| Net income | −$129.4M | −$204.5M | −$250.2M | −$183.1M | −$234.6M | −$343.0M | −$274.4M |
| Net margin | −19692.1% | −2636.3% | −2349.5% | −216.2% | −180486.2% | −562285.2% | −762355.6% |
| EPS (diluted) | −$480.80 | −$313.80 | −$36.80 | −$14.80 | −$18.70 | −$26.23 | −$16.06 |
| Balance sheet | |||||||
| Cash and equivalents | $96.7M | $140.4M | $293.8M | $123.6M | $145.6M | $105.6M | $60.2M |
| Total assets | — | $908.3M | $1.13B | $937.6M | $750.0M | $490.9M | $340.1M |
| Total liabilities | — | $189.8M | $197.6M | $104.3M | $95.1M | $108.0M | $91.8M |
| Shareholders' equity | −$111.1M | −$292.5M | $929.8M | $833.3M | $655.0M | $382.8M | $248.2M |
| Cash flow | |||||||
| Operating cash flow | $39.5M | −$160.9M | −$126.2M | −$169.6M | −$163.7M | −$162.4M | −$150.0M |
| Capital expenditure | $16.0M | $51.5M | $65.5M | $24.3M | $2.69M | $464.0K | $780.0K |
| Free cash flow | $23.4M | −$212.4M | −$191.8M | −$193.8M | −$166.4M | −$162.9M | −$150.8M |
| Share buybacks | $185.0K | $11.8M | $0 | $0 | — | — | — |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $34.0K | $11.0K | $7.00K | $8.00K | $15.0K | $6.00K | $2.00K | $4.00K |
| Growth (year over year) | +36.0% | −15.4% | +133.3% | −38.5% | −55.9% | −45.5% | −71.4% | −50.0% |
| Operating income | −$50.5M | −$201.1M | −$57.4M | −$47.1M | −$37.3M | −$127.6M | −$44.3M | −$47.3M |
| Operating margin | −148544.1% | −1828609.1% | −819528.6% | −589250.0% | −248353.3% | −2127400.0% | −2213050.0% | −1183425.0% |
| Net income | −$44.6M | −$191.9M | −$52.2M | −$42.7M | −$38.8M | −$140.7M | −$24.2M | −$44.8M |
| Net margin | −131126.5% | −1744863.6% | −745642.9% | −533550.0% | −258973.3% | −2345383.3% | −1207650.0% | −1118875.0% |
| EPS (diluted) | −$3.48 | −$14.36 | −$3.54 | −$2.89 | −$2.13 | −$7.50 | −$1.10 | −$1.92 |
| Balance sheet | ||||||||
| Cash and equivalents | $100.3M | $105.6M | $120.3M | $98.8M | $123.6M | $60.2M | $90.8M | $73.0M |
| Total assets | $619.2M | $490.9M | $429.8M | $385.5M | $408.0M | $340.1M | $350.6M | $311.2M |
| Total liabilities | $88.5M | $108.0M | $93.3M | $86.5M | $78.8M | $91.8M | $77.0M | $77.3M |
| Shareholders' equity | $530.7M | $382.8M | $336.5M | $298.9M | $329.1M | $248.2M | $273.7M | $233.8M |
| Cash flow | ||||||||
| Operating cash flow | −$35.0M | −$47.2M | −$54.7M | −$34.5M | −$28.6M | −$32.3M | −$38.5M | −$33.9M |
| Capital expenditure | $59.0K | $44.0K | $246.0K | $168.0K | $62.0K | $304.0K | $89.0K | $256.0K |
| Free cash flow | −$35.1M | −$47.3M | −$55.0M | −$34.6M | −$28.6M | −$32.6M | −$38.6M | −$34.2M |
From Lyell Immunopharma's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
No recent news mentioning Lyell Immunopharma in our feed yet.